No. | Age/Sex | Contrast Enhance-ment | Hemor-rhage | Necro-sis | Vasogenic Edema | Mass Effect | Signal Heterogeneity | Involvement of Corpus Callosum | Crossing Midline | MR Grade of Tumor | WHO Grade of Tumor | nCBV | nCBF | nMTT |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 20/M | HE | – | – | + | + | HT | + | + | HG | I | 1.92 | 0.58 | 3.55 |
2 | 27/F | NCE | – | – | + | + | HO | – | – | LG | II | 1.07 | 1.48 | 0.83 |
3 | 34/M | NCE | – | CD | + | ++ | HT | + | + | LG | II | 0.94 | 1.26 | 1.07 |
4 | 56/F | HE | – | + | ++ | ++ | HT | – | – | HG | II | 1.56 | 1.07 | 1.94 |
5 | 34/F | NCE | – | – | – | + | HO | – | – | LG | II | 1.72 | 1.43 | 1.08 |
6 | 18/F | HE | – | + | – | + | HT | – | – | HG | III | 2.26 | 1.53 | 1.41 |
7 | 39/M | HE | – | + | + | + | HT | – | – | HG | III | 2.21 | 1.23 | 1.71 |
8 | 57/M | HE | + | + | + | +++ | HT | – | – | HG | III | 5.39 | 6.84 | 2.63 |
9 | 68/M | NCE | – | + | + | + | HT | – | – | LG | III | 3.7 | 3.75 | 0.92 |
10 | 39/F | HE | + | + | ++ | +++ | HT | + | + | HG | III | 2.61 | 1.65 | 1.68 |
11 | 34/M | NCE | – | CD | – | ++ | HT | + | + | LG | III | 1.5 | 0.78 | 1.32 |
12 | 64/M | PNE | + | + | ++ | +++ | HT | + | + | HG | IV | 1.96 | 1.19 | 1.78 |
13 | 39/F | PNE | – | + | ++ | +++ | HT | + | – | HG | IV | 2.05 | 1.07 | 1.51 |
14 | 55/F | PNE | – | + | ++ | +++ | HT | + | + | HG | IV | 3.95 | 2.87 | 1.11 |
15 | 60/M | PNE | + | + | +++ | +++ | HT | + | – | HG | IV | 2.86 | 2.49 | 0.74 |
16 | 69/M | PNE | – | + | + | ++ | HT | – | – | HG | IV | 1.12 | 1.69 | 1.04 |
17 | 66/F | HE | – | + | + | + | HT | + | – | HG | IV | 5.3 | 6.16 | 0.77 |
18 | 46/M | HE | + | + | ++ | ++ | HT | + | + | HG | IV | 4.3 | 6.27 | 0.63 |
19 | 57/M | PNE | – | + | +++ | +++ | HT | – | – | HG | IV | 3.61 | 4.91 | 0.83 |
Note:—HE indicates heterogeneous enhancement; NCE, no contrast enhancement; PNE, peripheral nodular enhancement; CD, cystic degeneration; HT, heterogenous; HO, homogeneous; HG, high grade; LG, low grade; +, present; −, absent.